||In a similar phase
I clinical study based on immunotherapy by WT1 in patients with breast
cancer, lung cancer, myelodisplasia and acute myelocytic leukemia, Oka et
al. (Proc Natl Acad Sci USA 101 (38): 13885-90, 2004) found reduction of
leukemic blast cells in leukemia, a reduction in sizes and markers of other
tumors and a correlation between increase and the frequency of cytotoxic T
lymphocytes specific against WT1 after vaccination against it, resulting in
a regression of cancer without damage to normal tissues.